Replies to post #185743 on Biotech Values

[jaybe]

I think it was the NHL data...low ORR of 37% together with safety signals...Grade 3/4 adverse events (>=5%) include thrombocytopenia (37%), neutropenia (22%), anemia (16%), fatigue (12%), leukopenia (10%) and hyponatremia (10%). The most common Grade 1/2 adverse events were: nausea (63%), anorexia (52%), fatigue (46%), and vomiting (36%) that tend to lessen in severity with supportive care and were seen less frequently following cycle 1.